Frontlight ResearchEarly access
Taking people in SpainPhase 1
Comparing a proposed nivolumab copy with Opdivo after melanoma surgery
Compares how the body handles JPB898 and Opdivo in adults after melanoma surgery.
Key facts
- Who runs it
- H e x a l AG
- Where
- Badajoz, Barcelona, Cáceres, Granada, Jerez De La Frontera, Las Palmas de Gran Canaria, Lleida, Madrid, Majadahonda, Málaga, Oviedo, Pozuelo de Alarcón, Sabadell, San Cristóbal de La Laguna, Santander, Sevilla, Torrejón de Ardoz, and Valencia, SpainSee the 22 sitesAlso in 4 other countries, 14 sites
- Trial code
- Registry title
- A PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III melanoma in the adjuvant setting
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 89 people, planned
- Started
- 10 Feb 2026
- Expected to end
- 30 Sept 2028
- Type of study
- Interventional
- Record updated
- 11 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose stage IIB, IIC or III melanoma has been surgically removed and who need adjuvant treatment (treatment after surgery). It compares JPB898 with Opdivo.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Melanoma stage IIB, IIC or III, removed by surgery, needing adjuvant treatment
Where in Spain
Also in 4 other countries, 14 sites
- Hospital Universitario de BadajozBadajoz, SpainTaking people
- Hospital Clinic de BarcelonaBarcelona, SpainTaking people
- Hospital de la Santa Creu i Sant PauBarcelona, SpainTaking people
- Hospital Universitari Dexeus Grupo QuironsaludBarcelona, SpainTaking people
- Hospital San Pedro De AlcántaraCáceres, SpainTaking people
- Hospital Universitario Clínico San CecilioGranada, SpainTaking people
- Hospital Jerez Puerta Del Sur Grupo Hla S.A.Jerez De La Frontera, SpainTaking people
- Complejo Hospitalario Universitario Insular Materno InfantilLas Palmas de Gran Canaria, SpainTaking people
- Micancer Center S.L.P.Lleida, SpainTaking people
- Hospital Beata María AnaMadrid, SpainTaking people
- Hospital Universitario 12 de OctubreMadrid, SpainTaking people
- MD Anderson Cancer CenterMadrid, SpainTaking people
- Hospital Universitario Puerta de Hierro de MajadahondaMajadahonda, SpainTaking people
- Hospital Universitario Regional de MálagaMálaga, SpainTaking people
- Hospital Universitario Central De AsturiasOviedo, SpainTaking people
- Hospital Universitario Quironsalud MadridPozuelo de Alarcón, SpainTaking people
- Parc Tauli Hospital UniversitariSabadell, SpainTaking people
- Hospital Universitario de CanariasSan Cristóbal de La Laguna, SpainTaking people
- Hospital Universitario Marqués de ValdecillaSantander, SpainTaking people
- University Hospital Virgen Del Rocio S.L.Sevilla, SpainTaking people
- Hospital Universitario de TorrejonTorrejón de Ardoz, SpainTaking people
- Fundación Instituto Valenciano de OncologíaValencia, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Comparing a proposed nivolumab copy with Opdivo after melanoma surgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 11 November 2026